Advertisement

Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study

  • H. Gutzmann
  • D. Hadler
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 54)

Summary

The 2-year efficacy and safety of idebenone were studied in a prospective, randomized, double-blind multicentre study in 3 parallel groups of patients with dementia of the Alzheimer type (DAT) of mild to moderate degree. A total of 450 patients were randomized to either placebo for 12 months, followed by idebenone 90 mg tid for another 12 months (n = 153) or idebenone 90 mg tid for 24 months (n = 148) or 120 mg tid for 24 months (n = 149). The primary outcome measure was the total score of the Alzheimer’s Disease Assessment Scale (ADAS-Total) at month 6. Secondary outcome measures were the ADAS cognitive (ADAS-Cog) and noncognitive score (ADAS-Noncog), the clinical global response (CGI-Improvement), the SKT neuropsychological test battery, and the Nurses’ Observation Scale for Geriatric Patients (NOSGER-Total and IADL subscale). Safety parameters were adverse events, vital signs, ECG and clinical laboratory parameters. During the placebo controlled period (the first year of treatment), idebenone showed statistically significant dose-dependent improvement in the primary efficacy variable ADAS-Total and in all the secondary efficacy variables. There was no evidence for a loss of efficacy during the second year of treatment, as a further improvement of most efficacy variables was found in the second year in comparison to the results at the 12 months visit. Also, a clear dose effect relationship (placebo/90mg < idebenone 90mg < idebenone 120mg) was maintained throughout the second year of treatment. This suggests that idebenone exerts its beneficial therapeutic effects on the course of the disease by slowing down its progression. Safety and tolerability of idebenone were good and similar to placebo during the first year of treatment and did not change during the second year.

Keywords

Secondary Efficacy Anti Dementia Drug Secondary Efficacy Variable Beneficial Therapeutic Effect Clinical Laboratory Parameter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, rev. APA, Washington, DCGoogle Scholar
  2. CPMP Working Party on Efficacy of Medicinal Products (1992) Antidementia medicinal products. Note for guidance (Draft 5). Commission of the European Communities, BrusselsGoogle Scholar
  3. Erzigkeit H (1989) SKT: Ein Kurztest zur Erfassung von Gedächtnis- und Aufmerksamkeitsstörungen (4th ed.) [SKT: A short test to assess impairment of memory and attention]. Beltz Test, WeinheimGoogle Scholar
  4. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198PubMedCrossRefGoogle Scholar
  5. Gutzmann H, Hadler D, Erzigkeit H (1997) Long-term treatment of Alzheimer’s disease with idebenone. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewki HM (eds) Alzheimer’s disease: biology, diagnosis and therapeutics. John Wiley & Sons, New York, pp 687–705Google Scholar
  6. Hachinski VC, Illiff LD, Zihlka E, DuBoulay GH, McAllister VL, Marshall R, Ross-Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32: 632–637PubMedCrossRefGoogle Scholar
  7. Kanowski S, Ladurner G, Maurer K, Oswald WD, Stein U (1990) Empfehlungen zur Evaluierung der Wirksamkeit von Nootropika. Z Gerontopsychol-psychiatr 3: 67–79Google Scholar
  8. Kern U, Menges K (1992) Proof of efficacy of nootropics for the indication “dementia” (Phase III) — Recommendations. Pharmacopsychiatry 25: 126–135CrossRefGoogle Scholar
  9. Leber P (1996) Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 [Suppl 1]: 31–35PubMedCrossRefGoogle Scholar
  10. Lienert GA (1967) Testaufbau und Testanalyse, 2nd ed. [Test construction and test analysis]. Beltz, WeinheimGoogle Scholar
  11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department Health & Human Services Task Force on Alzheimer’s disease. Neurology 34: 939–944PubMedCrossRefGoogle Scholar
  12. National Institute of Mental Health (1976) Clinical Global Impressions. In: Guy W (ed) EDCEU assessment manual for psychopharmacology, rev ed. NIMH, Rockville, MD, pp 217–222Google Scholar
  13. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141: 1356–1364PubMedGoogle Scholar
  14. Sano M, et al (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222PubMedCrossRefGoogle Scholar
  15. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denario M, Marigliano V, Tammaro A, Fioravanti M (1992) Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 15: 249–260PubMedCrossRefGoogle Scholar
  16. Spiegel R, Brunner C, Ermini-Fünfschilling D, Monsch A, Notter M, Puxty J, Tremmel L (1991) A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses’ Observation Scale for Geriatric Patients). J Am Geriatr Soc 39: 339–347PubMedGoogle Scholar
  17. Weyer G, Ihl R, Mohs RC, Schambach M, Denkel A, Kaiser-Kehl H (1993) Validierungsuntersuchungen zu einer deutschen Version der Alzheimer’s Disease Assessment Scale ADAS [Investigations on the validity of a German version of the Alzheimer’s Disease Assessment Scale ADAS]. Z Gerontopsychol-psychiatr 6: 67–81Google Scholar
  18. Weyer G, Erzigkeit H, Hadler D, Kubicki S (1996) Efficacy and safety of idebenone in the long-term treatment of Alzheimer’s disease: a double-blind, placebo-controlled multicentre study. Hum Psychopharmacol 11: 53–65CrossRefGoogle Scholar
  19. Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann W (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 11: 340–350Google Scholar
  20. World Medical Association (1989) Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects (Amended by the 41st World Medical Assembly, Hong Kong, September 1989)Google Scholar

Copyright information

© Springer-Verlag/Wien 1998

Authors and Affiliations

  • H. Gutzmann
    • 1
  • D. Hadler
    • 2
  1. 1.Abteilung für GerontopsychiatrieKrankenhaus Hellersdorf, ö.B. Wilhelm-Griesinger-KrankenhausBerlinFederal Republic of Germany
  2. 2.Takeda Europe Research & Development Centre GmbHFrankfurtFederal Republic of Germany

Personalised recommendations